Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell–Depleting Therapy With COVID-19: A Target Trial Emulation Study
Early outpatient nirmatrelvir/ritonavir significantly lowers the risk of COVID-19-related hospitalization or death in patients on BCDT. Molnupiravir showed a nonsignificant trend toward benefit. These findings support prioritizing nirmatrelvir/ritonavir for high-risk immunocompromised populations.
Authors
- Leonard H. Calabrese (ORCID: https://orcid.org/0000-0002-1789-4923)
- Cassandra Calabrese (ORCID: https://orcid.org/0000-0002-8773-7739)
- Abhijit Duggal (ORCID: https://orcid.org/0000-0003-4220-2359)
- Gretchen L. Sacha (ORCID: https://orcid.org/0000-0002-0070-8100)
- Xiaofeng Wang (ORCID: https://orcid.org/0000-0001-8212-6931)
- Shuaiqi Huang (ORCID: https://orcid.org/0000-0001-5161-246X)
- Yiying Fan (ORCID: https://orcid.org/0000-0002-2569-5334)
- Y. Wang (ORCID: https://orcid.org/0000-0002-4663-6202)
- Shravan Kethireddy
Institutions
- Cleveland State University (US)
- Cleveland Clinic (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1093/cid/ciaf521
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 2.79